期刊
JOURNAL OF INHERITED METABOLIC DISEASE
卷 42, 期 6, 页码 1054-1063出版社
WILEY
DOI: 10.1002/jimd.12067
关键词
CPS1-deficiency; liver-humanized mice; urea cycle defects
资金
- CIMED, Clinical Innovative Medicine
- Vetenskapradet the Torsten och Ragnar Soderberg Stiftelse
- European Unions's Seventh Framework Programme [602757]
- Swiss National Science Foundation [310030_162547, 310030_153196]
- Swiss National Science Foundation (SNF) [310030_162547] Funding Source: Swiss National Science Foundation (SNF)
A liver-humanized mouse model for CPS1-deficiency was generated by the high-level repopulation of the mouse liver with CPS1-deficient human hepatocytes. When compared with mice that are highly repopulated with CPS1-proficient human hepatocytes, mice that are repopulated with CPS1-deficient human hepatocytes exhibited characteristic symptoms of human CPS1 deficiency including an 80% reduction in CPS1 metabolic activity, delayed clearance of an ammonium chloride infusion, elevated glutamine and glutamate levels, and impaired metabolism of [N-15]ammonium chloride into urea, with no other obvious phenotypic differences. Because most metabolic liver diseases result from mutations that alter critical pathways in hepatocytes, a model that incorporates actual disease-affected, mutant human hepatocytes is useful for the investigation of the molecular, biochemical, and phenotypic differences induced by that mutation. The model is also expected to be useful for investigations of modified RNA, gene, and cellular and small molecule therapies for CPS1-deficiency. Liver-humanized models for this and other monogenic liver diseases afford the ability to assess the therapy on actual disease-affected human hepatocytes, in vivo, for long periods of time and will provide data that are highly relevant for investigations of the safety and efficacy of gene-editing technologies directed to human hepatocytes and the translation of gene-editing technology to the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据